Ionis Pharmaceuticals reaches 52-week high amid positive trial results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2024
0mins
Should l Buy IONS?
Source: TipRanks
Ionis Pharmaceuticals Inc. saw a price increase of 5.51% as it reached a 52-week high, reflecting strong investor interest in the stock.
This surge is attributed to the successful Phase 3 trial results for Bepirovirsen in chronic hepatitis B treatment, demonstrating a significant functional cure rate. The trials involved over 1,800 patients across 29 countries, indicating a major advancement in treatment options and a strong market potential for the drug, which could address the needs of over 250 million people globally.
The positive results not only enhance Ionis's reputation in the biopharmaceutical sector but also position the company for substantial financial benefits, including up to $150 million in milestone payments from its collaboration with GSK, further solidifying its market presence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 75.660
Low
65.00
Averages
92.67
High
110.00
Current: 75.660
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
Biogen Unveils New Research Data on Spinal Muscular Atrophy
- High-Dose Nusinersen Research: Biogen presented long-term data on high-dose nusinersen at the 2026 Muscular Dystrophy Association conference, indicating potential benefits for spinal muscular atrophy patients, which may drive further market adoption globally.
- Salanersen Clinical Progress: New Phase 1b data illustrate the potential of salanersen in spinal muscular atrophy, and with Phase 3 studies commencing, it is expected to provide more effective treatment options, enhancing Biogen's competitiveness in this field.
- Global Regulatory Advances: The high-dose regimen of nusinersen has been approved in Japan, the EU, and Switzerland, and is under FDA review in the U.S., with a decision anticipated by April 3, 2026, which would further solidify Biogen's leadership in the SMA treatment market.
- Strategic Investment and Collaboration: Biogen's partnership with Ionis Pharmaceuticals for the development of salanersen demonstrates its ongoing commitment to innovative drug development, aiming to meet the growing treatment needs of spinal muscular atrophy patients.
See More
Ionis Pharmaceuticals Unveils New Data for DAWNZERA at AAAAI 2026
- Clinical Data Presentation: Ionis Pharmaceuticals will present new data for DAWNZERA (donidalorsen) at the 2026 AAAAI Annual Meeting, emphasizing its clinical value for hereditary angioedema (HAE) patients, potentially leading to significant improvements in attack frequency and quality of life.
- Research Highlights: The presentation includes analyses from the OASIS-HAE and OASISplus studies, indicating DAWNZERA's appeal in long-term prophylactic treatment, particularly for patients switching from other therapies, showcasing its competitive market potential.
- Extensive Poster Displays: Ionis will conduct eight poster presentations at the conference, covering various aspects from patient-reported disease control to unmet treatment needs, further solidifying its leadership position in HAE treatment.
- Broad Market Prospects: With HAE affecting over 20,000 individuals, DAWNZERA, as the first RNA-targeted medicine, is expected to become the prophylactic treatment of choice for HAE patients, addressing their urgent need for reduced attack frequency and severity.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Olezarsen
- FDA Priority Review: Ionis Pharmaceuticals announced that its drug olezarsen for severe hypertriglyceridemia has received FDA Priority Review, with a PDUFA target date of June 30, 2026, which will expedite its market entry to meet urgent patient needs for new treatment options.
- Clinical Trial Results: In the Phase 3 CORE and CORE2 studies, olezarsen demonstrated a statistically significant reduction in triglyceride levels of up to 72% and an 85% reduction in acute pancreatitis events, indicating its substantial potential to improve patient health outcomes.
- Market Demand: Approximately 3 million people in the U.S. suffer from severe hypertriglyceridemia, with over 1 million classified as high-risk; the limited efficacy of current treatments highlights the critical need for olezarsen to provide new hope and reduce the risk of acute pancreatitis.
- Drug Mechanism: Olezarsen works by lowering the production of apoC-III in the liver, which regulates triglyceride metabolism, and is already approved in the U.S. and EU for patients with familial chylomicronemia syndrome, showcasing its broad application prospects in treating hypertriglyceridemia.
See More
Ionis Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Ionis Pharmaceuticals reported $944 million in revenue for 2025, a 34% year-over-year increase, with commercial product sales contributing $436 million and R&D collaborations generating $508 million, showcasing the company's strong market performance and diversified revenue streams.
- Successful Product Launches: The independent launches of TRYNGOLZA and DAWNZERA mark a significant milestone for Ionis in 2025, with TRYNGOLZA exceeding market expectations and DAWNZERA projected to exceed $500 million in sales potential, further solidifying the company's market position.
- Positive R&D Progress: Olezarsen achieved positive Phase III results in severe hypertriglyceridemia and received FDA breakthrough therapy designation, with plans to be launch-ready by June 2026, demonstrating the company's robust capabilities in drug development.
- Management Change: Ionis announced Holly Kordasiewicz as the new Chief Development Officer, reflecting strategic adjustments in the executive team to support future product development and market expansion.
See More
Ionis Pharmaceuticals Reports Better-Than-Expected Q4 Results
- Financial Performance Beat: Ionis Pharmaceuticals reported an adjusted loss of $1.15 for Q4, better than Wall Street's estimate of $1.32, although the stock is under pressure, indicating market concerns about future performance.
- Significant Sales Growth: The company achieved $203 million in sales for Q4, surpassing the consensus of $156.09 million, primarily driven by strong sales of Tryngolza (olezarsen), which contributed to a 64% year-over-year increase.
- Product Sales Highlights: Tryngolza generated net product sales of $50 million in Q4, a 56% increase over the prior quarter, while Dawnzera (donidalorsen) recorded $7 million in its first full quarter on the market, indicating strong market acceptance of new products.
- Cautious Future Outlook: Ionis expects fiscal 2026 sales between $800 million and $825 million, below the consensus of $909.84 million, and anticipates an adjusted operating loss of $500 million to $550 million, reflecting a cautious approach to future growth.
See More
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
Biogen Unveils New Research Data on Spinal Muscular Atrophy
- High-Dose Nusinersen Research: Biogen presented long-term data on high-dose nusinersen at the 2026 Muscular Dystrophy Association conference, indicating potential benefits for spinal muscular atrophy patients, which may drive further market adoption globally.
- Salanersen Clinical Progress: New Phase 1b data illustrate the potential of salanersen in spinal muscular atrophy, and with Phase 3 studies commencing, it is expected to provide more effective treatment options, enhancing Biogen's competitiveness in this field.
- Global Regulatory Advances: The high-dose regimen of nusinersen has been approved in Japan, the EU, and Switzerland, and is under FDA review in the U.S., with a decision anticipated by April 3, 2026, which would further solidify Biogen's leadership in the SMA treatment market.
- Strategic Investment and Collaboration: Biogen's partnership with Ionis Pharmaceuticals for the development of salanersen demonstrates its ongoing commitment to innovative drug development, aiming to meet the growing treatment needs of spinal muscular atrophy patients.
See More
Ionis Pharmaceuticals Unveils New Data for DAWNZERA at AAAAI 2026
- Clinical Data Presentation: Ionis Pharmaceuticals will present new data for DAWNZERA (donidalorsen) at the 2026 AAAAI Annual Meeting, emphasizing its clinical value for hereditary angioedema (HAE) patients, potentially leading to significant improvements in attack frequency and quality of life.
- Research Highlights: The presentation includes analyses from the OASIS-HAE and OASISplus studies, indicating DAWNZERA's appeal in long-term prophylactic treatment, particularly for patients switching from other therapies, showcasing its competitive market potential.
- Extensive Poster Displays: Ionis will conduct eight poster presentations at the conference, covering various aspects from patient-reported disease control to unmet treatment needs, further solidifying its leadership position in HAE treatment.
- Broad Market Prospects: With HAE affecting over 20,000 individuals, DAWNZERA, as the first RNA-targeted medicine, is expected to become the prophylactic treatment of choice for HAE patients, addressing their urgent need for reduced attack frequency and severity.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Olezarsen
- FDA Priority Review: Ionis Pharmaceuticals announced that its drug olezarsen for severe hypertriglyceridemia has received FDA Priority Review, with a PDUFA target date of June 30, 2026, which will expedite its market entry to meet urgent patient needs for new treatment options.
- Clinical Trial Results: In the Phase 3 CORE and CORE2 studies, olezarsen demonstrated a statistically significant reduction in triglyceride levels of up to 72% and an 85% reduction in acute pancreatitis events, indicating its substantial potential to improve patient health outcomes.
- Market Demand: Approximately 3 million people in the U.S. suffer from severe hypertriglyceridemia, with over 1 million classified as high-risk; the limited efficacy of current treatments highlights the critical need for olezarsen to provide new hope and reduce the risk of acute pancreatitis.
- Drug Mechanism: Olezarsen works by lowering the production of apoC-III in the liver, which regulates triglyceride metabolism, and is already approved in the U.S. and EU for patients with familial chylomicronemia syndrome, showcasing its broad application prospects in treating hypertriglyceridemia.
See More
Ionis Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Ionis Pharmaceuticals reported $944 million in revenue for 2025, a 34% year-over-year increase, with commercial product sales contributing $436 million and R&D collaborations generating $508 million, showcasing the company's strong market performance and diversified revenue streams.
- Successful Product Launches: The independent launches of TRYNGOLZA and DAWNZERA mark a significant milestone for Ionis in 2025, with TRYNGOLZA exceeding market expectations and DAWNZERA projected to exceed $500 million in sales potential, further solidifying the company's market position.
- Positive R&D Progress: Olezarsen achieved positive Phase III results in severe hypertriglyceridemia and received FDA breakthrough therapy designation, with plans to be launch-ready by June 2026, demonstrating the company's robust capabilities in drug development.
- Management Change: Ionis announced Holly Kordasiewicz as the new Chief Development Officer, reflecting strategic adjustments in the executive team to support future product development and market expansion.
See More
Ionis Pharmaceuticals Reports Better-Than-Expected Q4 Results
- Financial Performance Beat: Ionis Pharmaceuticals reported an adjusted loss of $1.15 for Q4, better than Wall Street's estimate of $1.32, although the stock is under pressure, indicating market concerns about future performance.
- Significant Sales Growth: The company achieved $203 million in sales for Q4, surpassing the consensus of $156.09 million, primarily driven by strong sales of Tryngolza (olezarsen), which contributed to a 64% year-over-year increase.
- Product Sales Highlights: Tryngolza generated net product sales of $50 million in Q4, a 56% increase over the prior quarter, while Dawnzera (donidalorsen) recorded $7 million in its first full quarter on the market, indicating strong market acceptance of new products.
- Cautious Future Outlook: Ionis expects fiscal 2026 sales between $800 million and $825 million, below the consensus of $909.84 million, and anticipates an adjusted operating loss of $500 million to $550 million, reflecting a cautious approach to future growth.
See More
